Drug Trial Radar · NCT05683470
Expanded Access RBS2418 Treatment
Last checked: Nov 19, 2026Latest source record: Feb 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
No longer available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Riboscience, LLC.Industry
- Sponsor type
- Industry
- Collaborators
- Dr. Bertrand Tuan
- First posted
- Jan 13, 2023
Design
- Study type
- Expanded access
- Who can join
- Female only
Summary
As written by the sponsor on the registry.
This is an expanded access treatment protocol designed to provide access of RBS2418 to a single patient with pancreatic cancer.
Conditions
- Expanded Access in Pancreatic Cancer
Interventions
RBS2418Drug
RBS2418 will be administered orally at 200 mg two times per day (BID).
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.